UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1788) 1788
vision disorders - chemically induced (1437) 1437
male (1005) 1005
science & technology (997) 997
life sciences & biomedicine (963) 963
female (955) 955
adult (782) 782
middle aged (658) 658
ophthalmology (421) 421
aged (403) 403
abridged index medicus (287) 287
adolescent (225) 225
vision disorders - diagnosis (213) 213
animals (200) 200
neurosciences & neurology (179) 179
visual acuity (168) 168
child (165) 165
visual fields - drug effects (160) 160
anticonvulsants - adverse effects (159) 159
eye diseases - chemically induced (153) 153
vision disorders - physiopathology (150) 150
retinal diseases - chemically induced (148) 148
visual acuity - drug effects (140) 140
clinical neurology (138) 138
vision disorders - etiology (126) 126
time factors (120) 120
visual fields (119) 119
vigabatrin - adverse effects (115) 115
risk factors (111) 111
electroretinography (108) 108
eye diseases (103) 103
retina - drug effects (100) 100
retrospective studies (100) 100
follow-up studies (97) 97
retina (97) 97
general & internal medicine (95) 95
dose-response relationship, drug (92) 92
medicine, general & internal (91) 91
neurosciences (89) 89
vision (86) 86
fluorescein angiography (85) 85
genetic structures (85) 85
aged, 80 and over (83) 83
child, preschool (82) 82
research article (80) 80
vigabatrin (79) 79
pharmacology & pharmacy (76) 76
research (76) 76
health aspects (74) 74
treatment outcome (73) 73
epilepsy - drug therapy (72) 72
ethambutol - adverse effects (72) 72
vision disorders (72) 72
visual field tests (72) 72
drug therapy (68) 68
infant (68) 68
tomography, optical coherence (67) 67
complications and side effects (64) 64
young adult (63) 63
color vision defects - chemically induced (62) 62
vision, ocular - drug effects (61) 61
medicine & public health (60) 60
vision disorders - epidemiology (58) 58
care and treatment (57) 57
toxicology (57) 57
eye (56) 56
toxicity (56) 56
anticonvulsants - therapeutic use (55) 55
magnetic resonance imaging (55) 55
psychiatry (54) 54
methanol - poisoning (53) 53
headache - chemically induced (52) 52
sense organs (52) 52
surgery (52) 52
analysis (51) 51
acute disease (50) 50
pediatrics (50) 50
retinal diseases - diagnosis (50) 50
glaucoma (49) 49
clinical trials as topic (48) 48
mice (47) 47
nausea - chemically induced (47) 47
neurology (47) 47
optic nerve diseases - chemically induced (46) 46
prospective studies (46) 46
chloroquine - adverse effects (45) 45
optic neuritis - chemically induced (45) 45
pregnancy (45) 45
epilepsy (44) 44
causes of (43) 43
color perception - drug effects (43) 43
disease models, animal (43) 43
rats (43) 43
occupational diseases - chemically induced (42) 42
patients (42) 42
tuberculosis, pulmonary - drug therapy (42) 42
antineoplastic agents - adverse effects (41) 41
drug administration schedule (41) 41
vision disorders - drug therapy (41) 41
visual acuity - physiology (41) 41
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1634) 1634
German (101) 101
French (83) 83
Japanese (39) 39
Polish (25) 25
Russian (20) 20
Spanish (15) 15
Italian (11) 11
Czech (9) 9
Dutch (9) 9
Swedish (9) 9
Danish (7) 7
Chinese (4) 4
Portuguese (4) 4
Hebrew (3) 3
Norwegian (3) 3
Romanian (3) 3
Croatian (1) 1
Finnish (1) 1
Hungarian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: a cancer journal for clinicians, ISSN 0007-9235, 07/2013, Volume 63, Issue 4, pp. 249 - 279
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for... 
toxicity | kinase inhibitors | therapeutic index | targeted agents | mechanism‐based toxicity | immunotherapeutic agents | off‐target toxicity | mechanism-based toxicity | off-target toxicity | Life Sciences & Biomedicine | Oncology | Science & Technology | Mood Disorders - chemically induced | Drug Eruptions - etiology | Peripheral Nervous System Diseases - chemically induced | Bone Marrow Diseases - chemically induced | Cachexia - chemically induced | Endocrine System Diseases - chemically induced | Pleural Effusion - chemically induced | Humans | Drug Eruptions - therapy | Immune System Diseases - chemically induced | Lung Diseases, Interstitial - chemically induced | Thrombocytopenia - chemically induced | Diarrhea - chemically induced | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Hyperbilirubinemia - chemically induced | Venous Thromboembolism - chemically induced | Vision Disorders - chemically induced | Hemorrhage - chemically induced | Heart Diseases - chemically induced | Hyperlipidemias - chemically induced | Magnesium - blood | Antimitotic agents | Drugs | Prevention | Complications and side effects | Drug targeting | Antineoplastic agents | Health aspects | Risk factors | Proteins | Side effects | Genomics | Cytotoxicity | Molecular biology | Cancer therapies | Cells | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of the American Dental Association, ISSN 0002-8177, 05/2011, Volume 142, Issue 5, pp. 531 - 539
Background. The authors used comprehensive national registry and clinical data to conduct a study of adverse drug reactions (ADRs), in particular neurosensory... 
Drugs | Consumer product safety | Lingual nerve | Trigeminal nerve | Safety management | Alveolar nerve | Pharmacology | Nerve block' risk assessment | Facial nerves | Local anesthetics | Life Sciences & Biomedicine | Dentistry, Oral Surgery & Medicine | Science & Technology | Lidocaine - adverse effects | Mepivacaine - administration & dosage | Trigeminal Nerve Injuries | Hearing Loss - etiology | Humans | Middle Aged | Sensation Disorders - etiology | Male | Prilocaine - adverse effects | Young Adult | Facial Pain - chemically induced | Facial Paralysis - chemically induced | Nerve Block - adverse effects | Injections - adverse effects | Anesthetics, Local - adverse effects | Vision Disorders - chemically induced | Aged, 80 and over | Adult | Female | Facial Pain - etiology | Prilocaine - administration & dosage | Anesthetics, Local - administration & dosage | Hearing Loss - chemically induced | Diplopia - chemically induced | Sensation Disorders - chemically induced | Trigeminal Nerve Diseases - chemically induced | Adverse Drug Reaction Reporting Systems | Trigeminal Nerve Diseases - etiology | Carticaine - adverse effects | Mepivacaine - adverse effects | Needles - adverse effects | Lidocaine - administration & dosage | Databases as Topic | Injections - instrumentation | Taste Disorders - etiology | Trigeminal Nerve - drug effects | Denmark | Aged | Carticaine - administration & dosage | Taste Disorders - chemically induced | Facial Paralysis - etiology | Diplopia - etiology | Vision Disorders - etiology | Care and treatment | Practice | Adverse and side effects | Anesthetics | Complications and side effects | Dental hygiene | Market share | Mouth | Analysis | Distribution | Dental care | Injuries | Methods | Dentists | Anesthesia | Side effects | Neurotoxicity | Injections | Index Medicus | Dentistry
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2016, Volume 123, Issue 6, pp. 1386 - 1394
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 09/2014, Volume 61, Issue 9, pp. 1644 - 1672
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose‐escalation... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Epilepsia (Copenhagen), ISSN 0013-9580, 10/2017, Volume 58, Issue 10, pp. 1734 - 1741
Summary Objective Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE‐HS) is a common epilepsy syndrome that is often poorly controlled by... 
Drug response | Efficacy | Adverse drug reactions | Retention | Seizure freedom | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Pregabalin - therapeutic use | Triazines - therapeutic use | Humans | Middle Aged | Epilepsy, Temporal Lobe - drug therapy | Epilepsy, Temporal Lobe - physiopathology | Male | Sclerosis | Young Adult | Amines - therapeutic use | Vision Disorders - chemically induced | Adult | Female | Valproic Acid - therapeutic use | Retrospective Studies | gamma-Aminobutyric Acid - therapeutic use | Epilepsy, Temporal Lobe - pathology | Databases, Factual | Diplopia - chemically induced | Cyclohexanecarboxylic Acids - therapeutic use | Carbamazepine - analogs & derivatives | Vertigo - chemically induced | Dizziness - chemically induced | Anticonvulsants - therapeutic use | Carbamazepine - therapeutic use | Treatment Outcome | Hippocampus - pathology | Lethargy - chemically induced | Fructose - therapeutic use | Fructose - analogs & derivatives | Vigabatrin - therapeutic use | Adolescent | Aged | Ataxia - chemically induced | Benzodiazepines - therapeutic use | Medical research | Care and treatment | Anticonvulsants | Medicine, Experimental | Temporal lobe epilepsy | Seizures (Medicine) | Comparative analysis | Topiramate | Temporal lobe | Gabapentin | Epilepsy | Clinical trials | Valproic acid | Antiepileptic agents | Carbamazepine | Vertigo | Oxcarbazepine | Convulsions & seizures | Drowsiness | Ataxia | Hippocampus | Lamotrigine | Index Medicus
Journal Article